Ranbaxy Completes Merger with Sun Pharma: 5 Facts
Founded in 1961, India’s largest drug maker by sales closed on Monday after 54 years of being an independent company n the industry.
Here are 5 facts about Ranbaxy:
1) Ranbaxy started as a distribution firm for a Japanese Manufacturer in 1937 and was scaled to new heights by Parvinder Singh from 1962. It went public in 1973 and the turning point was when it entered the US market in 1998 as the first foreign generics manufacturer to sell drugs in the US.
2) The company went trough a series of transition from 1999 to 2008. In 2008, the Singh family sold their 33.5 per cent stake to the Japanese drugmaker Daiichi Sankyo for $2 billion. In total, Daiichi Sankyo paid a total of $4.6 billion to acquire Ranbaxy in 2008.
3) Following the ban by the FDA to sell about 30 of its drugs in the US, the company faced major crisis in 2008. In 2009, they were accused by the FDA of falsifying data and test results in drug applications. Reviews of drugs made at a plant in northern India were halted. The matter was settled in the US courts with a fine of $500 million, the largest-ever settlement for a generic drugmaker over drug safety, according to the US government.
4) On April 7, 2014 Sun Pharmaceutical and Daiichi Sankyo jointly announced the sale of entire 63.4 per cent share from Daiichi Sankyo to Sun Pharma in a $4 billion all share deal.
5) This merger has created the largest pharmaceutical company in India and the fifth largest specialty generics company in the world.
On February 2, 2017 The Ministry of Health and Family Welfare has announced Medical Devices Rules, 2017 that separates regulatory norms for manufacturing medical devices from drugs. The rules will come into effect from January […]Read More
Maharashtra Food and Drug Administration (FDA) has directed all 306 blood banks in the state to submit applications of renewal of licenses by 31st December 2016 to carry out timely inspections and approvals. There are […]Read More
Indian syringes and needles market is expected to grow at a CAGR of 15% by 2020. This growth is mainly because of India’s large pool of patients, increase in healthcare expenditure, increase in healthcare awareness […]Read More
The Ministry of Health’s Food Safety Standards Authority of India has come out with quality and safety standards to regulate the standards and quality of health supplements, nutraceuticals, food (special dietary care, medicinal purpose, functional […]Read More
On Monday, Indian food safety watchdog the Food Safety and Standards Authority of India (FSSAI) announced that health supplements cannot be sold as medicines at all and also fixed the permissible limits of various ingredients […]Read More
Now a new survey shows that, natural products continue to remain top of mind for many women when it comes to the personal care beauty products. The second annual Green Beauty Barometer survey questioned more […]Read More
The United States remains the biggest market for Korean cosmetic products and nowadays Korean investors are venturing into Indian cosmetic market. The Korea Trade Investment Promotion Agency (KOTRA) launched at least 10 Korean cosmetics brands […]Read More
The first Medical Device Regulatory Summit in India is being held at Holiday Inn Mumbai International Airport on 29 November 2016. Morulaa HealthTech is pleased to partner at this event. Medical Device Regulatory Summit 2016, […]Read More